Biotech · Private company · Mountain View, CA, US
Rejuvenation Technologies, Inc.
Track this companyFree. Adds Rejuvenation Technologies, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards6
- Advancing a telomere extension biologic to treat alcohol-associated liver damage to INDFiscal year 2026 · $2.1MNIH RePORTER 1SB1AA033292-01 · fetched Nov 12, 2026
- Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinicFiscal year 2026 · $1.1MNIH RePORTER 3R44TR005328-02S1 · fetched Nov 12, 2026
- Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinicFiscal year 2025 · $1NIH RePORTER 5R44TR005328-02 · fetched Nov 12, 2026
- Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells Fiscal year 2024 · $325KNIH RePORTER 1R43GM153144-01 · fetched Nov 12, 2026
- Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinicFiscal year 2024 · $1.1MNIH RePORTER 1R44TR005328-01 · fetched Nov 12, 2026
- TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitisFiscal year 2024 · $1.9MNIH RePORTER 5R44AA028749-03 · fetched Nov 12, 2026